Post-remission therapy with allogeneic hematopoietic-cell transplant (alloHSCT) is a potentially curative therapy for eligible patients that consists of pretransplant cytoreductive conditioning and an immunologic graft-versus-leukemia effect that occurs when the donor’s immune cells attack the transplant recipient’s leukemia.
- AlloHSCT is often given to patients with higher-risk disease who likely would not respond as well to other traditional approaches1
Allogeneic transplant is potentially curative for eligible patients with AML in first CR. 50%-60% of patients with AML with intermediate or high-risk cytogenetics achieve cure following first CR.2
Significant comorbidities can prevent patients from being eligible for allogeneic transplant, and treatment must be planned accordingly for these patients.2